CG Oncology Historical PE Ratio
This CGON historical PE ratio page, which was last updated 11/13/2026, presents historical price to earnings information for CG Oncology under both the TTM method and
the annualized method, and presented in both tabular and graphical format for ease of study.
CGON Historical PE Ratio Notes
— CG Oncology (NASDAQ: CGON) is a biotechnology company focused on developing & commercializing innovative immunotherapies for the treatment of bladder cancer, with its lead product candidate, cretostimogene grenadenorepvec, currently in late-stage clinical trials. Unlike established pharmaceutical companies that have steady sales & earnings, CG Oncology is in a pre-revenue stage—meaning it does not yet generate significant product revenue, as its therapies are still under clinical development. This has a direct impact on the company’s historical price-to-earnings (P/E) ratio: because CG Oncology either has minimal earnings or operates at a net loss, you’ll likely find that the historical P/E ratio is extremely high or simply not meaningful (often shown as “N/A”) for past periods. For early-stage biotech firms like CGON, investors tend to focus more on clinical trial progress & regulatory milestones rather than traditional valuation metrics like P/E, since earnings typically don’t materialize until late in development or after drug approval. When reviewing historical charts & tables, you’ll notice that price movements are driven more by trial results or FDA updates than by profitability trends. Understanding this context is key before attempting to draw conclusions from CGON’s historical P/E data.
How should the CGON historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?
✔️Accepted answer:
There are a number of different approaches when it comes to calculating a historical PE ratio for a company like CG Oncology. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this CGON Historical PE Ratio page.
What is the average historical PE for CGON based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?
✔️Accepted answer:
The CGON historical PE ratio using the annualized quarterly earnings method works out to NA.
What is the average historical PE for CGON based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?
✔️Accepted answer:
The CGON historical PE ratio using the TTM earnings method works out to NA.
On this page we presented the
CGON Historical PE Ratio information for CG Oncology' stock.
The average CGON historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CGON historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.
Let's now compare this CGON historical PE result, against the recent PE: when this page was posted on 11/12/2026, the most recent closing price for CGON had been 70.15, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.
For self directed investors doing their due diligence on CGON or any other given stock, valuation analysis for CGON
can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis
as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.
That's why we bring you
HistoricalPERatio.com to make it easy for investors to investigate
CG Oncology PE history or the past PE information for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for earnings
surprises history (beat/miss data) as well as next earnings dates for CGON. Thanks for visiting, and the next
time you need to research
CGON Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your
go-to historical PE ratio research resource of choice.